OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) to include three new indications: treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and reducing the risk of recurrent DVT and PE following initial treatment.
Related Content:
News